Pathogenesis and the Future of AD Treatment Epidemiology of AD ISAAC Global Prevalence of Eczema by Region AD and Other Skin Allergies US Centers for Disease Control AD Prevalence United States ID: 684723
Download Presentation The PPT/PDF document "Essential Updates in Atopic Dermatitis:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Essential Updates in Atopic Dermatitis:Slide2Slide3Slide4Slide5
Pathogenesis and the Future of AD TreatmentSlide6
Epidemiology of ADSlide7
ISAAC Global Prevalence of Eczema by RegionSlide8
AD and Other Skin Allergies
US Centers for Disease ControlSlide9
AD Prevalence -- United StatesSlide10
Diagnosis and Clinical PresentationSlide11
Differential Diagnosis of ADSlide12
Severity of ADSlide13
Severity of AD Comparison of Physician and Patient RatingsSlide14
Risk Factors for ADAtopic March HypothesisSlide15
Risk Factors for ADFamily HistorySlide16
FLG Mutations, Filaggrin, and Epidermal Barrier FunctionSlide17
Pathogenesis of ADSlide18
Pathogenesis: Immune DysregulationSlide19Slide20
AD and Quality of LifeSlide21
AD and QoLAdultsSlide22
AD and Sleep DisturbancesChildrenSlide23
Comorbidities -- Obesity and Metabolic SyndromePediatric PatientsSlide24
Comorbidities -- Cardiovascular DiseaseAdult PatientsSlide25
Comorbidities: Mental IllnessPediatric PatientsSlide26
Comorbidities -- ADHDAdult PatientsSlide27
Comorbidities -- Mental IllnessAdult PatientsSlide28
Current Standard of CareSlide29
Targeted Agents for ADSlide30
Dupilumab: Phase 3 DataSlide31
Nemolizumab: Phase 2 DataSlide32
Other Targeting Agents Under Investigation for Moderate to Severe ADSlide33
Concluding RemarksSlide34
AbbreviationsSlide35
Abbreviations (cont)Slide36
Abbreviations (cont)